VAXCYTE INC (PCVX)
US92243G1085 - Common Stock
PCVX Stock Earnings: Vaxcyte Beats EPS for Q1 2024
PCVX stock results show that Vaxcyte beat analyst estimates for earnings per share the first quarter of 2024.
PCVX Stock Earnings: Vaxcyte Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vaxcyte (NASDAQ:PCVX) just reported results for the first quarter of 2024.Vaxcy...
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
Vaxcyte Larger Than S&P 500 Component Ralph Lauren
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
SAN CARLOS, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering...
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
-- Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series by the End of the First Quarter of...
Vaxcyte GAAP EPS of -$4.14 misses by $0.65 (NASDAQ:PCVX)
Vaxcyte reports FY 2023 financial results, with a GAAP EPS miss of $0.65.
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-- VAX-31 Adult Program Phase 1/2 Study Enrollment Complete; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- --...
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
SAN CARLOS, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it will report financial results for the fourth quarter and full year 2023 after market close on February 27, 2024. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a business update.
Interesting PCVX Put And Call Options For January 2025
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
SAN CARLOS, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity...
Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
SAN CARLOS, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity...
Vaxcyte Announces Pricing of $750 Million Public Offering
Vaxcyte Announces Pricing of $750 Million Public Offering
SAN CARLOS, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity...
Vaxcyte announces commencement of proposed public offering (NASDAQ:PCVX)
Vaxcyte announces the commencement of a public offering of common stock and pre-funded warrants, with an option for underwriters to purchase additional...
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
SAN CARLOS, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity...
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
-- Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Phase 1/2 Study (n=1,015) Expected in Third Quarter of 2024 -- -- VAX-31 is Designed...
Vaxcyte Moves Up In Market Cap Rank, Passing Whirlpool
First Week of March 15th Options Trading For Vaxcyte (PCVX)
Vaxcyte Appoints Whitney Jones as Chief People Officer
Vaxcyte Appoints Whitney Jones as Chief People Officer
-- Ms. Jones Joins Vaxcyte With Over 20 Years of Experience Leading People and Culture Strategies Across Multiple Industries -- SAN CARLOS, Calif., Jan. ...
'Top Pick for 2024': Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales
Needham analyst Joseph Stringer reiterated a Buy rating on Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT),
Vaxcyte stock slips after pipeline updates (NASDAQ:PCVX)
Vaxcyte (PCVX) stock drop after biotech updated on its clinical pipeline, including a late-stage program for its lead vaccine candidate, VAX-24. Read more here.
Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise
-- Company Doses First Participants in Phase 2 Portion of Ongoing VAX-31 Phase 1/2 Study in Adults Following Independent Review of Phase 1 Safety and...
Vaccine Player Vaxcyte Can Potentially Disrupt Pfizer's 20-Plus-Year Near Monopoly, Says Analyst
Mizuho Securities initiated coverage on Vaxcyte Inc (NASDAQ: PCVX), a vaccine company targeting bacterial infectious diseases (primarily for disease prevention).